Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE These patients were noted to be younger (59 versus 61 years, p < 0.001) and less likely to have insulin-dependent diabetes (3.0 versus 4.4%, p < 0.001), preoperative dyspnea (2.2 versus 6.0%, p < 0.001), COPD (3.0 versus 4.2%, p = 0.011), and hypertension (40.7 versus 46.9%, p < 0.001) than patients who stayed longer. 31686161 2020
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE CAD or COPD alone (C<sub>1</sub>) or hypertension (H) were associated with increased risk of new onset AF corresponding to HR between 1.44 and 1.64. 31711634 2020
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE In recent years, multiorgan clinical ultrasonography (pulmonary, cardiac and vascular) has emerged as a tool of considerable usefulness in managing patients with COPD in numerous situations, including the differential diagnosis of dyspnoea of uncertain origin, the assessment of the aetiology in episodes of exacerbation, detecting concomitant heart failure or associated pulmonary hypertension and as support in managing cardiovascular risk factors such as subclinical atherosclerosis. 31447107 2020
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. 30872017 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Significant risk factors for the competing risk regression for infection after heart transplantation include LVAD infection (HR 1.94, [95% CI] 1.11-3.39, P = .020) and recipient COPD (HR 2.14, [95% CI] 1.39-3.32, P = .001) when adjusted for recipient age, gender, hypertension, diabetes mellitus, and body mass index. 31403741 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE <b>Conclusion:</b> 6MWD and EID exhibit different determinants in COPD with a minor impact of comorbidities limited to hypertension in EID and to obesity, which was unexpectedly associated with less EID. 31308646 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Inhibitors of PDEs have already been approved for COPD and pulmonary hypertension. 30678501 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE Pooled prevalence for the most significant NCDs was a follows; cancer 8% (95% CI 6-10%), cardiovascular disease 38% (95% CI 33-42%), hypertension 39% (95% CI 32-47%), diabetes 14% (95% CI 12-16%), COPD prevalence estimates ranged from 4% to 18%.Heterogeneity across studies was high. 30590404 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE However, the proportion and number of Fas+ cells were elevated in obese patients, in non-smokers, and in patients suffering from COPD and hypertension. 30171418 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Women, who favoured prolapse surgery, were younger and in significant better health condition (less hypertension and COPD), but showed a significantly higher POP-Q stage compared to women choosing pessary treatment. 30656443 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE On multivariable analysis, preoperative factors associated with early discharge included younger age (OR 0.988, p < 0.001), non-obesity (OR 0.737, p = 0.001), those receiving neoadjuvant chemotherapy (OR 1.424, p < 0.001), and lack of COPD (OR 0.489, p = 0.005) or hypertension (OR 0.805, p = 0.007). 30680502 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE The remaining predictors were combined into the new simple C<sub>2</sub>HEST score: C<sub>2</sub>: CAD/COPD (1 point each); H: hypertension (1 point); E: elderly (age ≥ 75 years, 2 points); S: systolic HF (2 points); and T: thyroid disease (hyperthyroidism, 1 point). 30292759 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE Severe PH patients (mean pulmonary arterial pressure [mPAP] ≥35 mmHg) with COPD, iPAH, or CTEPH (n=24, 16, or 16, respectively) were included retrospectively between January 2008 and January 2017. 30809092 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE The determinants that affect the dynamics of QoL 1 year after PTE in patients with CTEPH were the presence of comorbidities (COPD and coronary artery disease) and adverse events in the early postoperative period (residual pulmonary hypertension, neurological complications, atrial fibrillation, and heart failure). 29678648 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Cardiopulmonary exercise test and PaO<sub>2</sub> in evaluation of pulmonary hypertension in COPD. 29339921 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE Comorbidities included the following: obesity (n = 95, 78.5%), hypertension (n = 72, 59.5%), cardiovascular disease (n = 42, 34.7%), diabetes (n = 40, 33.1%), COPD (n = 34, 28.1%), malignancy (n = 30, 24.8%), active smoker (n = 28, 23.1%), immunosuppression (n = 10, 8.3%), chronic corticosteroid use (n = 6, 5.0%), advanced age (n = 6, 5.0%), hypoalbuminemia (n = 3, 2.5%), and renal insufficiency (n = 1, 0.8%). 29063307 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Anemia is prevalent not only in COPD but also in pulmonary hypertension. 30139350 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE Comorbidities included hypertension (50%), COPD (33%) and diabetes mellitus (15%). 28730730 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE Comorbidities and their prevalence included, hypertension (68%), diabetes mellitus (35%), hyperlipidemia (36%), coronary artery disease (18%), chronic kidney disease (17%), congestive heart failure (18%) and COPD (24%). 30087233 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE <i>ACE</i> gene polymorphism is associated with COPD and COPD with pulmonary hypertension: a meta-analysis. 30147309 2018
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Furthermore, we investigated the association between spirometry measures, COPD, and echocardiographic pulmonary hypertension. 29229105 2017
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE For example, deprivation was most strongly associated with alcohol related diseases and COPD admission rates, while continuity of primary care was most strongly associated with admission rates for chronic diseases such as hypertension and iron-deficiency anaemia. 28545412 2017
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE Co-morbidities included hypertension (50%), COPD (33%) and diabetes mellitus (15%). 28834230 2017
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 Biomarker group BEFREE Other investigational compounds target specific aspects or complications of COPD such as mucus hypersecretion and pulmonary hypertension. 28790817 2017
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.100 GeneticVariation group BEFREE We found higher prevalences of previous coronary artery disease (CAD) (38%), other atherosclerotic diseases (20.4%), cardiac risk factors such as hypertension (84.3%), diabetes (49.1%), hyperlipidemia (50.9%), heart failure (42.6%), atrial fibrillation (AF) (25.0%), severe aortic stenosis (13.0%), severe mitral regurgitation (3.7%), and implantable devices (25.0%), and co-morbidities such as renal impairment (48.1%), COPD (12.0%), and previous stroke (6.5%). 28320990 2017